Tag: FDA

By Vigilare Biopharma March 15, 2026Pharmacovigilance

Pharmacovigilance Submission Documents in the United States

Globally, Pharmacovigilance (PV) is built on one central idea: the benefit–risk evaluation should not stop at approval; it must continue through the full drug development regulatory process and the product’s commercial lifecycle. It is no

Read More
By Vigilare Biopharma March 15, 2026Uncategorized

FDA Launches TEMPO What Medical Device Innovators Need to Know

Are you a medical device manufacturer working on digital therapeutics, remote monitoring tools, or AI-enabled care solutions for chronic disease management? If your innovation is outcome-based and driven by real-world data, you should pay close

Read More